GlassScriptPhysician profile
Sameer A Siddiqui
NPI 1366414864
$6,644.47
in general payments reported to CMS, 2019-2025
28 companies · $3,078 in 2025
The $3,078 reported for 2025 was more than what 87% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $575 · 2020: $123 · 2021: $736 · 2022: $574 · 2023: $980 · 2024: $580 · 2025: $3,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,204 · Travel and Lodging: $1,434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,204.04 |
| Travel and Lodging | $1,433.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Profound Medical Corp. | $2,339.60 | 2022-2025 | Tulsa-Pro |
| Boston Scientific Corporation | $1,432.87 | 2019-2025 | Lithovue, Lithoclast, Advance Xp |
| Intuitive Surgical, INC. | $508.78 | 2021-2025 | Da Vinci Surgical System |
| Calyxo, INC. | $451.60 | 2024-2025 | Cvac Aspiration System |
| Urogen Pharma, INC. | $307.64 | 2021-2025 | |
| Karl Storz Endoscopy-America | $292.56 | 2019-2024 | Flex-X, N.A. |
| Ambu INC. | $250.57 | 2021 | |
| Astellas Pharma US INC | $168.91 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $154.80 | 2025 | Adstiladrin |
| Janssen Scientific Affairs, LLC | $125.00 | 2019 | |
| Coloplast Corp | $111.43 | 2022-2024 | |
| Kerecis Limited | $75.00 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Depuy Synthes Sales INC. | $62.80 | 2022 | |
| Teleflex LLC | $61.83 | 2024 | Deflux |
| Pfizer INC. | $50.88 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $50.20 | 2024-2025 | |
| Medtronic, INC. | $43.06 | 2022-2025 | |
| Acera Surgical, INC. | $24.73 | 2024 | Restrata Wound Matrix |
| Sumitomo Pharma America, INC. | $24.64 | 2025 | Orgovyx |
| Myovant Sciences INC. | $21.66 | 2022 | |
| Myriad Genetic Laboratories, INC. | $18.57 | 2021 | |
| Olympus America INC. | $18.14 | 2025 | Itind System |
| Allergan, INC. | $14.00 | 2021 | |
| Abiomed | $13.82 | 2025 | |
| Bard Peripheral Vascular, INC. | $11.72 | 2020 | |
| Janssen Biotech, INC. | $9.66 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameer Siddiqui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.